Airway epithelial CFTR mRNA expression in cystic fibrosis patients after repetitive administration of a recombinant adenovirus
Summary
This summary is machine-generated.Adenovirus vectors safely deliver cystic fibrosis transmembrane conductance regulator (CFTR) cDNA to CF airways, but expression is transient and diminishes with repeated administration due to unknown mechanisms.
Area Of Science
- Gene Therapy
- Respiratory Medicine
- Molecular Biology
Background
- Cystic fibrosis (CF) is a genetic disorder affecting the lungs.
- Gene therapy aims to deliver functional CFTR cDNA to correct CFTR deficiency.
- Adenovirus vectors are being explored for gene delivery in CF.
Purpose Of The Study
- To evaluate the safety and efficacy of an adenovirus vector (Ad(GV)CFTR.10) for CFTR gene transfer.
- To assess dose-dependency and duration of CFTR expression in CF airway epithelium.
- To investigate the impact of repeated vector administration on gene expression.
Main Methods
- Adenovirus vector Ad(GV)CFTR.10 administered via endobronchial spray to individuals with CF.
- Doses ranged from 3 x 10^6 to 2 x 10^9 PFU over 9 months.
- CFTR mRNA levels (vector-derived vs. endogenous) measured pre-therapy and at 3 and 30 days post-therapy.
Main Results
- The Ad vector strategy was found to be safe.
- Vector-derived CFTR cDNA expression was dose-dependent after initial administration.
- Expression levels exceeded 5% of endogenous CFTR mRNA at higher doses but were transient (<30 days).
- Second administration yielded expression at intermediate doses; third administration showed no expression.
- Lack of sustained expression did not correlate with anti-adenovirus antibodies.
Conclusions
- Adenovirus vectors can deliver CFTR cDNA to CF airway epithelium, offering potential protection.
- Expression is transient and diminishes with repeated administration.
- Unknown mechanisms limit the efficacy of repeated adenovirus vector administration for sustained CFTR expression.
View abstract on PubMed